Brooklyn, NY – According to filings with the U.S. Securities and Exchange Commission, AzurRx BioPharma is raising $22,800,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Daniel Schneiderman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AzurRx BioPharma

AzurRx BioPharma is a clinical stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company’s lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). The company is headquartered in New York City, with scientific operations in Langlade, France and clinical operations in Hayward, California.

To learn more about AzurRx BioPharma, visit http://www.azurrx.com/

Contact:
Daniel Schneiderman, Chief Financial Officer
646-699-7855
https://www.linkedin.com/in/danschneiderman/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved